Top ▲

SERT

Click here for help

Target not currently curated in GtoImmuPdb

Target id: 928

Nomenclature: SERT

Systematic Nomenclature: SLC6A4

Family: Monoamine transporter subfamily

Contents:

Gene and Protein Information Click here for help
Species TM AA Chromosomal Location Gene Symbol Gene Name Reference
Human 12 630 17q11.2 SLC6A4 solute carrier family 6 member 4
Mouse 12 630 11 46.18 cM Slc6a4 solute carrier family 6 (neurotransmitter transporter, serotonin), member 4
Rat 12 630 10q24 Slc6a4 solute carrier family 6 member 4
Previous and Unofficial Names Click here for help
5-HTT | SERT1 | HTT | 5HT transporter | 5HTT | serotonin transporter | sodium-dependent serotonin transporter | solute carrier family 6 (neurotransmitter transporter), member 4 | solute carrier family 6 (neurotransmitter transporter, serotonin), member 4 | solute carrier family 6 (neurotransmitter transporter
Database Links Click here for help
Specialist databases
Bioparadigms SLC Tables SLC6A4 (Hs)
RESOLUTE SLC6A4 (Hs)
Other databases
Alphafold P31645 (Hs), Q60857 (Mm), P31652 (Rn)
ChEMBL Target CHEMBL228 (Hs), CHEMBL4642 (Mm), CHEMBL313 (Rn)
DrugBank Target P31645 (Hs)
Ensembl Gene ENSG00000108576 (Hs), ENSMUSG00000020838 (Mm), ENSRNOG00000003476 (Rn)
Entrez Gene 6532 (Hs), 15567 (Mm), 25553 (Rn)
Human Protein Atlas ENSG00000108576 (Hs)
KEGG Gene hsa:6532 (Hs), mmu:15567 (Mm), rno:25553 (Rn)
OMIM 182138 (Hs)
Pharos P31645 (Hs)
SynPHARM 83551 (in complex with escitalopram)
79385 (in complex with escitalopram)
83552 (in complex with paroxetine)
13002 (in complex with paroxetine)
UniProtKB P31645 (Hs), Q60857 (Mm), P31652 (Rn)
Wikipedia SLC6A4 (Hs)
Selected 3D Structures Click here for help
Image of receptor 3D structure from RCSB PDB
Description:  X-ray structure of the ts3 human serotonin transporter complexed with s-citalopram at the central and allosteric sites
PDB Id:  5I73
Ligand:  escitalopram
Resolution:  3.24Å
Species:  Human
References:  7
Image of receptor 3D structure from RCSB PDB
Description:  X-ray structure of the ts3 human serotonin transporter complexed with paroxetine at the central site
PDB Id:  5I6X
Ligand:  paroxetine
Resolution:  3.14Å
Species:  Human
References:  7
Substrates and Reaction Kinetics Click here for help
Substrate Sp. Property Value Units Standard property Standard value Assay description Assay conditions Comments Reference
5-hydroxytryptamine Substrate is endogenous in the given species Hs -
MDMA Hs -
p-chloroamphetamine Hs -
Stoichiometry Click here for help
1 5-HT:1 Na+:1 Cl- (in), + 1 K+ (out) [23]

Download all structure-activity data for this target as a CSV file go icon to follow link

Inhibitors
Key to terms and symbols View all chemical structures Click column headers to sort
Ligand Sp. Action Value Parameter Reference
paroxetine Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 10.1 pKd 7
⤷ pKd 10.1 (Kd 8x10-11 M) [7]
[3H]paroxetine Small molecule or natural product Ligand is labelled Ligand is radioactive Hs Inhibition 9.7 pKd
⤷ pKd 9.7 (Kd 2x10-10 M)
clomipramine Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 9.6 pKd 24
⤷ pKd 9.6 (Kd 2.8x10-10 M) [24]
escitalopram Small molecule or natural product Approved drug Primary target of this compound Ligand has a PDB structure Hs Inhibition 8.7 pKd 7
⤷ pKd 8.7 (Kd 2.1x10-9 M) [7]
fluvoxamine Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibition 8.7 pKd 24
⤷ pKd 8.7 (Kd 2.2x10-9 M) [24]
[3H]citalopram Small molecule or natural product Ligand is labelled Ligand is radioactive Hs Inhibition 8.3 pKd
⤷ pKd 8.3 (Kd 5x10-9 M)
atomoxetine Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 8.1 pKd 6
⤷ pKd 8.1 (Kd 8.9x10-9 M) [6]
protriptyline Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Inhibition 7.7 pKd 24
⤷ pKd 7.7 (Kd 1.96x10-8 M) [24]
nefazodone Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Inhibition 6.7 pKd 6
⤷ pKd 6.7 (Kd 2x10-7 M) [6]
clomipramine Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 9.7 pKi 24
⤷ pKi 9.7 (Ki 2.1x10-10 M) [24]
paroxetine Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 9.6 pKi 24
⤷ pKi 9.6 (Ki 2.5x10-10 M) [24]
sertraline Small molecule or natural product Approved drug Primary target of this compound Ligand has a PDB structure Hs Inhibition 9.1 pKi
⤷ pKi 9.1 (Ki 7.9x10-10 M)
vortioxetine Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Immunopharmacology Ligand Hs Inhibition 8.8 pKi 4
⤷ pKi 8.8 (Ki 1.6x10-9 M) [4]
fluoxetine Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Inhibition 8.5 pKi 24
⤷ pKi 8.5 (Ki 3x10-9 M) [24]
citalopram Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Inhibition 8.4 pKi 5
⤷ pKi 8.4 (Ki 4.38x10-9 M) [5]
Description: Displacement of [3H]citalopram from human SERT expressed in HEK293 cells.
H05 Small molecule or natural product Click here for species-specific activity table Rn Inhibition 8.3 pKi 27
⤷ pKi 8.3 (Ki 4.81x10-9 M) [27]
duloxetine Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 8.3 pKi 10
⤷ pKi 8.3 (Ki 5x10-9 M) [10]
fluvoxamine Small molecule or natural product Approved drug Ligand has a PDB structure Immunopharmacology Ligand Rn Inhibition 8.2 pKi 13
⤷ pKi 8.2 (Ki 6.5x10-9 M) [13]
Description: Inhibition of [3]5-HT uptake into rat astrocyte cultures.
nortriptyline Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 8.2 pKi 3
⤷ pKi 8.2 (Ki 6.98x10-9 M) [3]
dosulepin Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Inhibition 8.1 pKi 24
⤷ pKi 8.1 (Ki 8.6x10-9 M) [24]
desvenlafaxine Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Inhibition 7.8 pKi 9
⤷ pKi 7.8 (Ki 1.5x10-8 M) [9]
amoxapine Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Inhibition 7.7 pKi 3
⤷ pKi 7.7 (Ki 1.8x10-8 M) [3]
desipramine Small molecule or natural product Approved drug Ligand has a PDB structure Rn Inhibition 7.7 pKi 1
⤷ pKi 7.7 (Ki 2x10-8 M) [1]
imipramine Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 7.7 pKi 22
⤷ pKi 7.7 (Ki 2.03x10-8 M) [22]
Description: Displacement of [3H]citalopram from hSERT.
ziprasidone Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 7.3 pKi
⤷ pKi 7.3 (Ki 5.3x10-8 M)
lofepramine Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Inhibition 7.2 pKi 24
⤷ pKi 7.2 (Ki 6x10-8 M) [24]
lumateperone Small molecule or natural product Approved drug Click here for species-specific activity table Hs Inhibition 7.2 pKi 15,20
⤷ pKi 7.2 (Ki 6.2x10-8 M) [15,20]
doxepin Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 7.2 pKi 24
⤷ pKi 7.2 (Ki 6.8x10-8 M) [24]
amitriptyline Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 6.8 pKi 2
⤷ pKi 6.8 (Ki 1.41x10-7 M) [2]
trimipramine Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Inhibition 6.8 pKi 24
⤷ pKi 6.8 (Ki 1.49x10-7 M) [24]
desipramine Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 6.8 pKi 16
⤷ pKi 6.8 (Ki 1.63x10-7 M) [16]
Description: Assay using HEK-293 cells transfected with hSERT
sibutramine Small molecule or natural product Approved drug Click here for species-specific activity table Hs Inhibition 6.0 pKi 3
⤷ pKi 6.0 (Ki 1.108x10-6 M) [3]
phenelzine Small molecule or natural product Approved drug Click here for species-specific activity table Hs Inhibition <5.0 pKi 24
⤷ pKi <5.0 (Ki >1x10-5 M) [24]
vilazodone Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 8.8 – 9.3 pIC50 8,12
⤷ pIC50 8.8 – 9.3 (IC50 1.58x10-9 – 5x10-10 M) [8,12]
escitalopram Small molecule or natural product Approved drug Primary target of this compound Ligand has a PDB structure Hs Inhibition 9.0 pIC50 17
⤷ pIC50 9.0 (IC50 1x10-9 M) [17]
dapoxetine Small molecule or natural product Approved drug Primary target of this compound Hs Inhibition 8.9 pIC50 11
⤷ pIC50 8.9 (IC50 1.12x10-9 M) [11]
Description: Inhibition of the reuptake of [3H]5-HT
venlafaxine Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Inhibition 7.6 pIC50 18
⤷ pIC50 7.6 (IC50 2.7x10-8 M) [18]
milnacipran Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Inhibition 7.3 pIC50 25
⤷ pIC50 7.3 (IC50 5.012x10-8 M) [25]
levomilnacipran Small molecule or natural product Approved drug Primary target of this compound Click here for species-specific activity table Hs Inhibition 6.5 pIC50 26
⤷ pIC50 6.5 (IC50 3.2x10-7 M) [26]
ibogaine Small molecule or natural product Ligand has a PDB structure Hs Inhibition 6.3 pIC50 14
⤷ pIC50 6.3 (IC50 5x10-7 M) [14]
toludesvenlafaxine Small molecule or natural product Approved drug Click here for species-specific activity table Hs Inhibition 6.1 pIC50 21
⤷ pIC50 6.1 (IC50 7.23x10-7 M) [21]
norzotepine Small molecule or natural product Click here for species-specific activity table Hs Inhibition 5.2 pIC50 19
⤷ pIC50 5.2 (IC50 6.191x10-6 M) [19]
zotepine Small molecule or natural product Approved drug Click here for species-specific activity table Ligand has a PDB structure Hs Inhibition 5.1 pIC50 19
⤷ pIC50 5.1 (IC50 7.27x10-6 M) [19]
View species-specific inhibitor tables
Inhibitor Comments
Although nefazodone is claimed to be an inhibitor of the serotonin and norepinephrine transporters, the dopamine transporter appears to have a similar dissociation constant to the norepinephrine transporter [6].

Occupancy of the allosteric site by escitalopram sterically hinders ligand unbinding from the central site. This allows the drug to negatively regulate (inhibit) SERT activity [7].
Phenotypes, Alleles and Disease Models Click here for help Mouse data from MGI

Show »

Allele Composition & genetic background Accession Phenotype Id Phenotype Reference
Htr2atm1Grch|Htr2atm2Grch|Slc6a4+|Slc6a4tm1(cre)Grch Htr2atm1Grch/Htr2atm2Grch,Slc6a4tm1(cre)Grch/Slc6a4+
involves: 129S6/SvEvTac		 MGI:109521  MGI:96285  MP:0001362 abnormal anxiety-related response PMID: 16873667 
Htr1atm2Rhn|Slc6a4+|Slc6a4tm1(tTA)Cogr Htr1atm2Rhn/Htr1atm2Rhn,Slc6a4tm1(tTA)Cogr/Slc6a4+
involves: 129S1/Sv * BALB/cJ * C57BL/6 * CBA		 MGI:96273  MGI:96285  MP:0006276 abnormal autonomic nervous system physiology PMID: 18599790 
Htr1btm1Rhn|Slc6a4tm1Kpl Htr1btm1Rhn/Htr1btm1Rhn,Slc6a4tm1Kpl/Slc6a4tm1Kpl
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6		 MGI:96274  MGI:96285  MP:0000285 abnormal heart valve morphology PMID: 16380550 
Htr1atm2Rhn|Slc6a4+|Slc6a4tm1(tTA)Cogr Htr1atm2Rhn/Htr1atm2Rhn,Slc6a4tm1(tTA)Cogr/Slc6a4+
involves: 129S1/Sv * BALB/cJ * C57BL/6 * CBA		 MGI:96273  MGI:96285  MP:0004811 abnormal neuron physiology PMID: 18599790 
Htr1btm1Rhn|Slc6a4tm1Kpl Htr1btm1Rhn/Htr1btm1Rhn,Slc6a4tm1Kpl/Slc6a4tm1Kpl
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6		 MGI:96274  MGI:96285  MP:0003141 cardiac fibrosis PMID: 16380550 
Htr1atm2Rhn|Slc6a4+|Slc6a4tm1(tTA)Cogr Htr1atm2Rhn/Htr1atm2Rhn,Slc6a4tm1(tTA)Cogr/Slc6a4+
involves: 129S1/Sv * BALB/cJ * C57BL/6 * CBA		 MGI:96273  MGI:96285  MP:0005534 decreased body temperature PMID: 18599790 
Htr1btm1Rhn|Slc6a4tm1Kpl Htr1btm1Rhn/Htr1btm1Rhn,Slc6a4tm1Kpl/Slc6a4tm1Kpl
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6		 MGI:96274  MGI:96285  MP:0005140 decreased cardiac muscle contractility PMID: 16380550 
Htr1atm2Rhn|Slc6a4+|Slc6a4tm1(tTA)Cogr Htr1atm2Rhn/Htr1atm2Rhn,Slc6a4tm1(tTA)Cogr/Slc6a4+
involves: 129S1/Sv * BALB/cJ * C57BL/6 * CBA		 MGI:96273  MGI:96285  MP:0005333 decreased heart rate PMID: 18599790 
Htr1atm2Rhn|Slc6a4+|Slc6a4tm1(tTA)Cogr Htr1atm2Rhn/Htr1atm2Rhn,Slc6a4tm1(tTA)Cogr/Slc6a4+
involves: 129S1/Sv * BALB/cJ * C57BL/6 * CBA		 MGI:96273  MGI:96285  MP:0008770 decreased survivor rate PMID: 18599790 
Htr1btm1Rhn|Slc6a4tm1Kpl Htr1btm1Rhn/Htr1btm1Rhn,Slc6a4tm1Kpl/Slc6a4tm1Kpl
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6		 MGI:96274  MGI:96285  MP:0002795 dilated cardiomyopathy PMID: 16380550 
Htr1btm1Rhn|Slc6a4tm1Kpl Htr1btm1Rhn/Htr1btm1Rhn,Slc6a4tm1Kpl/Slc6a4tm1Kpl
involves: 129S1/Sv * 129S2/SvPas * 129X1/SvJ * C57BL/6		 MGI:96274  MGI:96285  MP:0003958 heart valve hyperplasia PMID: 16380550 
Htr1atm2Rhn|Slc6a4+|Slc6a4tm1(tTA)Cogr Htr1atm2Rhn/Htr1atm2Rhn,Slc6a4tm1(tTA)Cogr/Slc6a4+
involves: 129S1/Sv * BALB/cJ * C57BL/6 * CBA		 MGI:96273  MGI:96285  MP:0002083 premature death PMID: 18599790 
Clinically-Relevant Mutations and Pathophysiology Click here for help
Disease:  Anxiety
OMIM: 607834
Disease:  Obsessive-compulsive disorder; OCD
Disease Ontology: DOID:10933
OMIM: 164230

References

Show »

1. Altenbach RJ, Black LA, Strakhova MI, Manelli AM, Carr TL, Marsh KC, Wetter JM, Wensink EJ, Hsieh GC, Honore P et al.. (2010) Diaryldiamines with dual inhibition of the histamine H(3) receptor and the norepinephrine transporter and the efficacy of 4-(3-(methylamino)-1-phenylpropyl)-6-(2-(pyrrolidin-1-yl)ethoxy)naphthalen-1-ol in pain. J Med Chem, 53 (21): 7869-73. [PMID:20945906]

2. Arunotayanun W, Dalley JW, Huang XP, Setola V, Treble R, Iversen L, Roth BL, Gibbons S. (2013) An analysis of the synthetic tryptamines AMT and 5-MeO-DALT: emerging 'Novel Psychoactive Drugs'. Bioorg Med Chem Lett, 23 (11): 3411-5. [PMID:23602445]

3. Auerbach SS, DrugMatrix® and ToxFX® Coordinator National Toxicology Program. National Toxicology Program: Dept of Health and Human Services. Accessed on 02/05/2014. Modified on 02/05/2014. DrugMatrix, https://ntp.niehs.nih.gov/drugmatrix/index.html

4. Bang-Andersen B, Ruhland T, Jørgensen M, Smith G, Frederiksen K, Jensen KG, Zhong H, Nielsen SM, Hogg S, Mørk A et al.. (2011) Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem, 54 (9): 3206-21. [PMID:21486038]

5. Ben-Daniel R, Deuther-Conrad W, Scheunemann M, Steinbach J, Brust P, Mishani E. (2008) Carbon-11 labeled indolylpropylamine analog as a new potential PET agent for imaging of the serotonin transporter. Bioorg Med Chem, 16 (12): 6364-70. [PMID:18487050]

6. Carlier PR, Lo MM, Lo PC, Richelson E, Tatsumi M, Reynolds IJ, Sharma TA. (1998) Synthesis of a potent wide-spectrum serotonin-, norepinephrine-, dopamine-reuptake inhibitor (SNDRI) and a species-selective dopamine-reuptake inhibitor based on the gamma-amino alcohol functional group. Bioorg Med Chem Lett, 8 (5): 487-92. [PMID:9871604]

7. Coleman JA, Green EM, Gouaux E. (2016) X-ray structures and mechanism of the human serotonin transporter. Nature, 532 (7599): 334-9. [PMID:27049939]

8. Dawson LA, Watson JM. (2009) Vilazodone: a 5-HT1A receptor agonist/serotonin transporter inhibitor for the treatment of affective disorders. CNS Neurosci Ther, 15 (2): 107-17. [PMID:19499624]

9. Dreyfus N, Myers JK, Badescu VO, de Frutos O, de la Puente ML, Ding C, Filla SA, Fynboe K, Gernert DL, Heinz BA et al.. (2013) Discovery of a potent, dual serotonin and norepinephrine reuptake inhibitor. ACS Med Chem Lett, 4 (6): 560-4. [PMID:24900709]

10. Fish PV, Deur C, Gan X, Greene K, Hoople D, Mackenny M, Para KS, Reeves K, Ryckmans T, Stiff C et al.. (2008) Design and synthesis of morpholine derivatives. SAR for dual serotonin & noradrenaline reuptake inhibition. Bioorg Med Chem Lett, 18 (8): 2562-6. [PMID:18387300]

11. Gengo PJ, Giuliano F, McKenna KE et al.. (2005) Monoaminergic transporter binding and inhibition profile of dapoxetine, a medication for the treatment of premature ejaculation [abstract]. J Urol, 173: Abstract 878.

12. Heinrich T, Böttcher H, Gericke R, Bartoszyk GD, Anzali S, Seyfried CA, Greiner HE, Van Amsterdam C. (2004) Synthesis and structure--activity relationship in a class of indolebutylpiperazines as dual 5-HT(1A) receptor agonists and serotonin reuptake inhibitors. J Med Chem, 47 (19): 4684-92. [PMID:15341484]

13. Inazu M, Takeda H, Ikoshi H, Sugisawa M, Uchida Y, Matsumiya T. (2001) Pharmacological characterization and visualization of the glial serotonin transporter. Neurochem Int, 39 (1): 39-49. [PMID:11311448]

14. Kargbo RB. (2022) Ibogaine and Their Analogs as Therapeutics for Neurological and Psychiatric Disorders. ACS Med Chem Lett, 13 (6): 888-890. [PMID:35707155]

15. Li P, Zhang Q, Robichaud AJ, Lee T, Tomesch J, Yao W, Beard JD, Snyder GL, Zhu H, Peng Y et al.. (2014) Discovery of a tetracyclic quinoxaline derivative as a potent and orally active multifunctional drug candidate for the treatment of neuropsychiatric and neurological disorders. J Med Chem, 57 (6): 2670-82. [PMID:24559051]

16. Owens MJ, Morgan WN, Plott SJ, Nemeroff CB. (1997) Neurotransmitter receptor and transporter binding profile of antidepressants and their metabolites. J Pharmacol Exp Ther, 283 (3): 1305-22. [PMID:9400006]

17. Rotella DP, McFarlane GR, Greenfield A, Grosanu C, Robichaud AJ, Denny RA, Feenstra RW, Núñez-García S, Reinders JH, Neut Mv et al.. (2009) Tetrahydrocarbazole-based serotonin reuptake inhibitor/dopamine D2 partial agonists for the potential treatment of schizophrenia. Bioorg Med Chem Lett, 19 (19): 5552-5. [PMID:19720528]

18. Sabatucci JP, Mahaney PE, Leiter J, Johnston G, Burroughs K, Cosmi S, Zhang Y, Ho D, Deecher DC, Trybulski E. (2010) Heterocyclic cycloalkanol ethylamines as norepinephrine reuptake inhibitors. Bioorg Med Chem Lett, 20 (9): 2809-12. [PMID:20378347]

19. Shobo M, Kondo Y, Yamada H, Mihara T, Yamamoto N, Katsuoka M, Harada K, Ni K, Matsuoka N. (2010) Norzotepine, a major metabolite of zotepine, exerts atypical antipsychotic-like and antidepressant-like actions through its potent inhibition of norepinephrine reuptake. J Pharmacol Exp Ther, 333 (3): 772-81. [PMID:20223878]

20. Snyder GL, Vanover KE, Zhu H, Miller DB, O'Callaghan JP, Tomesch J, Li P, Zhang Q, Krishnan V, Hendrick JP et al.. (2015) Functional profile of a novel modulator of serotonin, dopamine, and glutamate neurotransmission. Psychopharmacology (Berl.), 232 (3): 605-21. [PMID:25120104]

21. Subbaiah MAM. (2019) Correction to "Triple Reuptake Inhibitors as Potential Therapeutics for Depression and Other Disorders: Design Paradigm and Developmental Challenges". J Med Chem, 62 (21): 10003. [PMID:31617718]

22. Sweetnam PM, Caldwell L, Lancaster J, Bauer Jr C, McMillan B, Kinnier WJ, Price CH. (1993) The role of receptor binding in drug discovery. J Nat Prod, 56 (4): 441-55. [PMID:8496700]

23. Talvenheimo J, Fishkes H, Nelson PJ, Rudnick G. (1983) The serotonin transporter-imipramine "receptor". J Biol Chem, 258 (10): 6115-9. [PMID:6853478]

24. Tatsumi M, Groshan K, Blakely RD, Richelson E. (1997) Pharmacological profile of antidepressants and related compounds at human monoamine transporters. Eur J Pharmacol, 340 (2-3): 249-58. [PMID:9537821]

25. Van Orden LJ, Van Dyke PM, Saito DR, Church TJ, Chang R, Smith JA, Martin WJ, Jaw-Tsai S, Stangeland EL. (2013) A novel class of 3-(phenoxy-phenyl-methyl)-pyrrolidines as potent and balanced norepinephrine and serotonin reuptake inhibitors: synthesis and structure-activity relationships. Bioorg Med Chem Lett, 23 (5): 1456-61. [PMID:23347683]

26. Vickers T, Dyck B, Tamiya J, Zhang M, Jovic F, Grey J, Fleck BA, Aparicio A, Johns M, Jin L et al.. (2008) Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors. Bioorg Med Chem Lett, 18 (11): 3230-5. [PMID:18468895]

27. Xu X, Wei Y, Guo Q, Zhao S, Liu Z, Xiao T, Liu Y, Qiu Y, Hou Y, Zhang G et al.. (2018) Pharmacological Characterization of H05, a Novel Serotonin and Noradrenaline Reuptake Inhibitor with Moderate 5-HT2A Antagonist Activity for the Treatment of Depression. J Pharmacol Exp Ther, 365 (3): 624-635. [PMID:29615471]

Contributors

Show »

How to cite this page